The treatment of HCC1806 BC cells with specific pharmacologic inhibitor or shRNA of DUSP9, significantly reduced DUSP9 levels and caused simultaneously reduction of the stem cells markers OCT4 and ALDH1. This evidence concerns the gene DUSP9 and breast cancer.